1-855-378-42281-855-378-4228
One of the out-patient rehab alternatives for people in Blue Mountain Lake who are battling with opioid abuse and addiction is called opioid maintenance therapy. Licensed clinics and doctors are authorized to administer specific medications to opioid addicted individuals, many that are opioids also and are addictive. With low amounts however, the client does not experience being high and also doesn't experience severe cravings and is not experiencing opioid withdrawal. Methadone is the first medication used for this reason, but there are other options to choose from.
Methadone is an opiate and can be taken at an out-patient medical center certified to dispense the med, that is taken on a daily basis as a pill or liquid. The price of the med is around one hundred and fifty dolloars a month. Buprenorphine is also an opioid-based med, and is a pill often taken every other day. But different from Methadone that can only be given in highly well-regulated clinics, Buprenorphine can be prescribed and administered in doctor's offices. The cost monthly of buprenorphine is approximately three hundred dollars /month for the generic of the medication. There is also a type of buprenorphine that contains naloxone, which is a med which reverses the effects of opiates. An individual consuming this version of the drug, AKA Suboxone, would find it more difficult to feel high from opioids if they relapsed while taking the drug. It is also taken every day, and costs about $450 a month. Naltrexone is an additional drug used in opioid maintenance therapy, but unlike the other medications aforementioned it's an opioid blocker and isn't an opioid. There is an option to take this medication as a monthly shot, and that is called Vivitrol. As an opioid blocker, the drug prevents an individual from getting high from opioids, and therefore lowers the risk associated with relapse. This daily shot costs anywhere from $1000 to $1200 monthly.
For All Alcohol and Drug Rehab Facilities In Blue Mountain Lake, Click Here.
